Pharmaceuticals Search Engine [selected websites]

Thursday, November 25, 2010

VirtuOx launches a patient centered Sleep Apnea education website

VirtuOxSeptember, 2010 - VirtuOx launches www.Apneabuster.com, a patient centered Sleep Apnea education website.

About Virtuox, Inc.

VirtuOx, Inc. is a privately held medical technology services company that provides diagnostic tools and services that enable a variety of healthcare organizations and professionals in diagnosing and treating Respiratory diseases through vertically integrated platforms, products and services. Virtuox’ platforms includes a Medicare approved, Independent Diagnostic Testing Facility (IDTF) that assists in the diagnosis and qualification of treatment options for Sleep Disorder Breathing and Respiratory Diseases in the home, industry leading web-based management applications that communicate with physicians, medical equipment providers and patients globally as well as product and distribution offerings.VirtuOx's Press Release -

Thursday, November 18, 2010

TONIX Pharmaceuticals : Analysis of Phase 2a Study of Very Low Dosage Cyclobenzaprine in Fibromyalgia Syndrome (FMS)

TONIX Pharmaceuticals (formerly known as Krele Pharmaceuticals)November 9, 2010 – For the First Time, Correlation Demonstrated between Sleep Stability and Reductions of Fatigue in FMS - Results Presented at the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) 2011 Annual Scientific Meeting - TONIX Pharmaceuticals (formerly known as Krele Pharmaceuticals), a specialty central nervous system (CNS) pharmaceutical company, announced results of a new analysis of a Phase 2a study, which previously demonstrated reduced pain, fatigue and tenderness in patients with Fibromyalgia Syndrome (FMS) following bedtime administration of very low dosage (VLD) cyclobenzaprine (CBP). According to the analysis, VLD CBP treatment was associated with reductions in an objective measure of non-REM sleep instability, referred to as Cyclic Alternating Patterns (CAP) A2 & A3; these reductions were statistically significantly correlated with diminished pre-sleep/p.m. fatigue in FMS. The findings are the subject of a poster presentation at the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) 2011 Annual Scientific Meeting.

Dr. Harvey Moldofsky, President and Medical Director, Centre for Sleep and Chronobiology, Toronto, Canada, and lead author of the study, commented, “Current treatments for FMS are inadequate, and there is substantial interest in the impact of improving sleep quality in these patients. Our analysis demonstrates improvements in FMS fatigue can be correlated with a therapeutic modality that normalizes nonrestorative sleep, and we believe this provides additional confirmation of the central importance of poor sleep quality in FMS.”... TONIX Pharmaceuticals' Press Release -

Thursday, November 11, 2010

Actavis : 180-day marketing exclusivity in the US for Zolpidem Tartrate extended-release tablets, USP 6,25mg CIV

Actavis19 OCT 2010 - Actavis has received approval from the FDA to market Zolpidem Tartrate Extended-Release Tablets, USP 6,25mg CIV in the United States. Distribution of the product has commenced.

As the first company to file an ANDA that contained a paragraph IV certification for Ambien® CR 6,25mg, Actavis has been awarded 180-day exclusivity to market this product.

Zolpidem Tartrate extended-release tablets 6,25mg, the generic equivalent of Ambien® CR 6,25mg by Sanofi-Aventis, had US sales of approximately USD129 million for the 12 months ending 30 June, 2010 (IMS Health data)... Actavis' Press Release -

Friday, November 5, 2010

Evotec : License and collaboration agreement with Jingxin Pharma for EVT 201

Evotec AG28 October 2010: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) announced that it has entered into a license and collaboration agreement with Zhejiang Jingxin Pharmaceutical Co., Ltd ("Jingxin Pharma") for EVT 201, a novel potential treatment for insomnia. The agreement grants Jingxin Pharma exclusive rights to develop and market the drug candidate in China. In return, Evotec will receive a small upfront payment, together with commercial milestones and significant royalties.

Zhejiang Jingxin Pharmaceutical Co., Ltd
Jingxin Pharma will initiate clinical trials with EVT 201 in China in 2011. All development costs will be borne by Jingxin Pharma. Evotec will have the right to reference clinical data produced by Jingxin Pharma to support potential further development of EVT 201 in other territories... Evotec's Press Release -